Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two ...

Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 while maintaining a Buy rating on the shares. Although the firm is ...

Fintel reports that on May 28, 2025, B of A Securities downgraded their outlook for Prothena (NasdaqGS:PRTA) from Neutral to Underperform. Analyst Price Forecast Suggests 1,045.01% Upside As of ...

Prothena’s management has responded by planning significant cost-cutting measures and exploring options to enhance shareholder value. Despite these setbacks, the company remains focused on its ...

Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target. This rating update came after Prothena Corporation’s (NASDAQ ...